Hi folks,
Can anyone enlighten me as to the advantages the APAS will offer over the existing culture plate reading technologies
from BD Kiestra, Copan et al?
LBT looks very tempting on fundamental analysis but as a medical scientist and having reviewed the company's literature/presentations I fail to see what is really 'first-in-class and disruptive' (as the LBT site states) about their
offering. Sure they may have a slightly BETTER imaging and interpretative system but how is it revolutionary and disruptive? Why do a lot of you feel they will dominate the market share?
Cheers
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.5¢ |
Change
0.004(19.1%) |
Mkt cap ! $44.16M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.7¢ | 2.2¢ | $222.5K | 9.367M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1835000 | 2.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 319865 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2025 (20 minute delay) ? |
| CC5 (ASX) Chart |